Propanc Biopharma, Inc. 8-K

What Happened

• Propanc Biopharma announced on July 8, 2026 that director Annie Van Broekhoven retired and resigned from the company's Board of Directors.
• The Board filled the vacancy the same day by appointing Carlo Campiciano to serve as a director until his resignation or removal.

Key Details

• Effective date of change: July 8, 2026.
• New director: Carlo Campiciano — qualified accountant, member of the Institute of Public Accountants (Australia), holds US GAAP certification.
• Education and experience: Master of Entrepreneurship and Innovation (Swinburne), Graduate Diploma in Computing (Monash Caulfield), Bachelor of Business (Accounting) (RMIT), Certificate in Corporate Governance; former CFO and Company Secretary of ASX-listed MedAdvisor Limited and part of its founding/IPO team.
• The company filed a Director Agreement with Mr. Campiciano as Exhibit 10.1 to the Form 8-K.

Why It Matters

• This is a board-level governance change: investors should note a seasoned finance executive with public-company CFO experience has joined the board, which may strengthen financial oversight.
• The filing is procedural and does not report changes to executive management, financial results, or material transactions beyond the appointment.